Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

One hundred and eighteen years have passed since Alzheimer's disease (AD) was first diagnosed by Alois Alzheimer as a multifactorial and complex neurodegenerative disorder with psychiatric components. 5 key findings →

Evidence: low

In AD-like mice surgery induced acute changes in amyloid-β; perioperative treatment with pVNS effectively reduced amyloid-β load, plaque sphericity, and neuronal loss. 5 key findings →

Evidence: low

Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Science Advances 2026-07-31

The accumulation of pathological four-repeat (4R) tau is central to several frontotemporal dementia (FTD) subtypes, but human neuronal models amenable to high-throughput screening of 4R tau-targeting therapies remain very limited. 1 key finding →

Evidence: low

Repulsive guidance molecule-a (RGMa) has emerged as a significant therapeutic target in a variety of neurological disorders, including neurodegenerative diseases and acute conditions. 1 key finding →

Evidence: low

This study aimed to examine the effects of aerobic and strength training methodologies, either combined with or without cognitive training, on mitigating cognitive decline. 5 key findings →

Participants: 56 Evidence: low

Type 2 Diabetes and Cognitive Decline: A Neurovascular Perspective

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Chronicle of Diabetes Research and Practice 2025-01-01

The manuscript provides a thorough analysis of the neurovascular and metabolic processes that contribute to cognitive deterioration in patients with Type 2 diabetes (T2D). 5 key findings →

Design: longitudinal study Evidence: moderate

For the interim analysis as of October 2024, the results of the MCI study arm are reported (n=42). 5 key findings →

Participants: 42 Evidence: high

Each 10% increase in UPF intake was associated with lower attention scores (-0.05 points) and higher dementia risk (+0.24 points), independent of Mediterranean diet adherence. 2 key findings →

Design: cross-sectional Evidence: low

Dementia affects over 55 million people globally, with early cognitive decline, such as Mild Cognitive Impairment (MCI), often preceding neurodegenerative diseases. 1 key finding →

Evidence: low

On average, people with dementia fall more often than their age-matched peers, with serious consequences, yet the underlying reasons remain poorly understood. 1 key finding →

Design: narrative review Evidence: low

Several interconnected themes were identified as potential resources that enable recovery from delirium: (a) social contact and recovery of social lives; (b) the need for information, support, and education; (c) personalisation and personhood; (d) relationship continuity with professional carers; (e) the experience and involvement of carers; and (f) treating the cause and healthy lifestyle. 3 key findings →

Evidence: low

We identified key limitations in traditional assessment methods and classified SS symptoms into five domains: psychomotor symptoms, cognitive and perceptual disturbances, mood and affective symptoms, psychosis, and disruptions in activities of daily living and instrumental activities of daily living. 4 key findings →

Evidence: low

Delirium: an urgent health priority in Australian hospitals

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Public Health Research & Practice 2026-05-26

Delirium is a common health problem with serious and long-lasting health consequences that disproportionately affects vulnerable population groups (especially older people with dementia or frailty). 3 key findings →

Evidence: low

Oropharyngeal dysphagia (OD) is a highly prevalent geriatric syndrome that remains underdiagnosed and undertreated, often resulting in severe nutritional and respiratory complications with poor clinical outcomes. 5 key findings →

Design: narrative review Evidence: moderate

The resulting framework is organized around 3 themes-vision, process, and impact-each containing guiding questions that encourage dialogical reflection and decision-making. 4 key findings →

Evidence: low

N = 48 community-based dyads completed the LEAD intervention, with N = 43 answering open-ended questions. 5 key findings →

Participants: 48 Evidence: low

AI/AN patients at the end-of-life were more likely to be hospitalized and less likely to use hospice compared with their NHW counterparts. 4 key findings →

Participants: 6,975 Evidence: low

Broad barriers identified in the outer setting of the implementation framework include sociocultural values and a lack of supportive policies, guidelines, and financing. 5 key findings →

Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed